» Authors » Nicolai Hartel

Nicolai Hartel

Explore the profile of Nicolai Hartel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 147
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Li M, Schulte N, Elting F, Winkler E, Hetjens S, Berger A, et al.
Oncol Res Treat . 2022 Jun; 45(11):670-680. PMID: 35675788
Introduction: Colorectal cancer (CRC) is a disease of older patients, but evidence-based guidelines for chemotherapy in older patients are scarce. Geriatric assessment (GA) evaluates a patient's functional status (FS) and...
2.
Betge J, Rindtorff N, Sauer J, Rauscher B, Dingert C, Gaitantzi H, et al.
Nat Commun . 2022 Jun; 13(1):3135. PMID: 35668108
Patient-derived organoids resemble the biology of tissues and tumors, enabling ex vivo modeling of human diseases. They have heterogeneous morphologies with unclear biological causes and relationship to treatment response. Here,...
3.
Betge J, Schulte N, Belle S, Zhan T, Krammer-Steiner B, Moulin J, et al.
J Geriatr Oncol . 2022 Jan; 13(5):662-666. PMID: 34991998
Background: Older patients with metastatic pancreatic cancer may suffer increased toxicity from intensive chemotherapy. Treatment individualization by geriatric assessment (GA) might improve functional outcome. Methods: We performed a multicenter, phase...
4.
Schulte N, Ebert M, Reissfelder C, Hartel N
Z Gastroenterol . 2020 Jun; 58(6):564-576. PMID: 32544966
Older patients (65 years and over) represent the majority of patients with a cancer diagnosis. For oesophageal carcinomas, the age peak is in the seventh to eighth decade of life....
5.
Gutting T, Schulte N, Belle S, Betge J, Hartel N, Wilke J, et al.
J Gastrointestin Liver Dis . 2019 Dec; 28(4):503-507. PMID: 31826054
Metastatic gastric cancer (GC) and oesophagogastric junctional (OGJ) adenocarcinoma have a poor clinical outcome with a high worldwide burden of disease. A 65-year old male patient with microcytic anemia was...
6.
Burgermeister E, Battaglin F, Eladly F, Wu W, Herweck F, Schulte N, et al.
EBioMedicine . 2019 Jul; 45:139-154. PMID: 31300350
Background: The identification of new biomarkers and the development of novel, targetable contexts of vulnerability are of urgent clinical need in drug-resistant metastatic colorectal cancer (mCRC). Aryl-Hydrocarbon-Receptor-Nuclear-Translocator-Like (ARNTL/BMAL1) is a...
7.
Herrmann S, Zhan T, Betge J, Rauscher B, Belle S, Gutting T, et al.
Mol Oncol . 2019 Jun; 13(8):1669-1683. PMID: 31254442
Monitoring the mutational patterns of solid tumors during cancer therapy is a major challenge in oncology. Analysis of mutations in cell-free (cf) DNA offers a noninvasive approach to detect mutations...
8.
Hirth M, Weiss C, Hardt P, Gubergrits N, Hartel N, Ebert M, et al.
Pancreas . 2019 May; 48(5):726-733. PMID: 31091222
Objectives: The pancreatic burnout hypothesis postulated an increasing absence of pain with simultaneous functional insufficiency in advanced stages of chronic pancreatitis (CP). However, the underlying data remain scarce and contradictory....
9.
Teufel A, Zhan T, Hartel N, Bornschein J, Ebert M, Schulte N
Cancer Lett . 2019 May; 456:80-87. PMID: 31051213
In recent years, immune checkpoint inhibitors (ICIs) were successfully introduced to cancer therapy and these drugs have already become essential for the treatment of various non-curable tumors. Compared to conventional...
10.
Hirth M, Hartel N, Weiss C, Hardt P, Gubergrits N, Ebert M, et al.
Digestion . 2019 Jan; 100(3):152-159. PMID: 30630169
Background: Several guidelines recommend the risk-adapted monitoring of patients with chronic pancreatitis (CP). However, dedicated risk stratification is widely missing in CP. Elderly-CP (disease onset with 60 or more years...